R E McLendon

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma
    Jill A Maxwell
    Department of Surgery, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Mol Cancer Ther 5:2531-9. 2006
  2. ncbi Multiple phenotypic changes in mice after knockout of the B3gnt5 gene, encoding Lc3 synthase--a key enzyme in lacto-neolacto ganglioside synthesis
    Chien Tsun Kuan
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    BMC Dev Biol 10:114. 2010
  3. ncbi Survival analysis of presumptive prognostic markers among oligodendrogliomas
    Roger E McLendon
    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 104:1693-9. 2005
  4. ncbi Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor
    R E McLendon
    Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA
    J Histochem Cytochem 48:1103-10. 2000
  5. ncbi Embryonal central nervous system neoplasms arising in infants and young children: a pediatric brain tumor consortium study
    Roger E McLendon
    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Arch Pathol Lab Med 135:984-93. 2011
  6. ncbi Glioneuronal tumors of the central nervous system
    Roger E McLendon
    Department of Pathology, Duke University Medical Center 3712, Davison Building, Room M216, Durham, NC 27710, USA
    Brain Tumor Pathol 19:51-8. 2002
  7. ncbi Second messenger systems in human gliomas
    Roger E McLendon
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Arch Pathol Lab Med 131:1585-90. 2007
  8. ncbi Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results
    D D Bigner
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 16:2202-12. 1998
  9. ncbi Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization
    S H Bigner
    Departments of Pathology, Duke University Medical Center, Durham, North Carolina, USA
    Am J Pathol 155:375-86. 1999
  10. ncbi DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma
    H S Friedman
    Department of Surgery, Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 16:3851-7. 1998

Detail Information

Publications108 found, 100 shown here

  1. ncbi Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma
    Jill A Maxwell
    Department of Surgery, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Mol Cancer Ther 5:2531-9. 2006
    ..The data also suggest that consideration be given to the large population of AGT-expressing cells within samples when therapeutic strategies based on tumor methylation are used...
  2. ncbi Multiple phenotypic changes in mice after knockout of the B3gnt5 gene, encoding Lc3 synthase--a key enzyme in lacto-neolacto ganglioside synthesis
    Chien Tsun Kuan
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    BMC Dev Biol 10:114. 2010
    ....
  3. ncbi Survival analysis of presumptive prognostic markers among oligodendrogliomas
    Roger E McLendon
    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 104:1693-9. 2005
    ..However, the authors questioned the relevance of genetic testing and measuring MGMT levels in tumors that were diagnostic of oligodendroglioma...
  4. ncbi Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor
    R E McLendon
    Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA
    J Histochem Cytochem 48:1103-10. 2000
    ....
  5. ncbi Embryonal central nervous system neoplasms arising in infants and young children: a pediatric brain tumor consortium study
    Roger E McLendon
    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Arch Pathol Lab Med 135:984-93. 2011
    ..Medulloblastomas (MBs) and atypical teratoid/rhabdoid tumors (AT/RTs) arising in infants and children can be difficult to distinguish; however, histologic characterization is prognostically important...
  6. ncbi Glioneuronal tumors of the central nervous system
    Roger E McLendon
    Department of Pathology, Duke University Medical Center 3712, Davison Building, Room M216, Durham, NC 27710, USA
    Brain Tumor Pathol 19:51-8. 2002
    ..For pathologists confronted by this growing array of tumors and subtypes, it is appropriate to focus on them and understand the differential diagnosis to be considered when confronted by them...
  7. ncbi Second messenger systems in human gliomas
    Roger E McLendon
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Arch Pathol Lab Med 131:1585-90. 2007
    ....
  8. ncbi Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results
    D D Bigner
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 16:2202-12. 1998
    ..To determine the maximum-tolerated dose (MTD) of iodine 131 (131I)-labeled 81C6 monoclonal antibody (mAb) in brain tumor patients with surgically created resection cavities (SCRCs) and to identify any objective responses to this treatment...
  9. ncbi Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization
    S H Bigner
    Departments of Pathology, Duke University Medical Center, Durham, North Carolina, USA
    Am J Pathol 155:375-86. 1999
    ....
  10. ncbi DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma
    H S Friedman
    Department of Surgery, Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 16:3851-7. 1998
    ....
  11. ncbi Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy
    G Akabani
    Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 46:947-58. 2000
    ....
  12. ncbi Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma
    John H Sampson
    Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 28:4722-9. 2010
    ..Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in glioblastoma multiforme (GBM) and other neoplasms...
  13. ncbi Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa)
    Amy B Heimberger
    Department of Surgery, Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 8:3496-502. 2002
    ..On the basis of these observations, we believe that clinical trials of ZD1839 against brain tumors expressing EGFR are warranted, but that special consideration should be given to tumors that coexpress EGFRvIII...
  14. ncbi Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
    D A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Br J Cancer 101:1986-94. 2009
    ..We evaluated bevacizumab with metronomic etoposide among recurrent malignant glioma patients in a phase 2, open-label trial...
  15. ncbi Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma
    H S Friedman
    Departments of Surgery, Medicine, Pathology, Radiology, and Community and Family Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 18:3522-8. 2000
    ..We conducted a phase I trial of carmustine (BCNU) plus O(6)-BG to define the toxicity and maximum-tolerated dose (MTD) of BCNU in conjunction with the preadministration of O(6)-BG with recurrent or progressive malignant glioma...
  16. ncbi Irinotecan therapy in adults with recurrent or progressive malignant glioma
    H S Friedman
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 17:1516-25. 1999
    ..To determine the activity, toxicity, and pharmacokinetics of irinotecan (CPT-11, Camptosar; Pharmacia & Upjohn, Kalamazoo, MI) in the treatment of adults with progressive, persistent, or recurrent malignant glioma...
  17. ncbi Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas
    I Cokgor
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 18:3862-72. 2000
    ....
  18. ncbi Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis
    T J Cummings
    Duke University Medical Center, Department of Pathology, Durham, NC 27710, USA
    Acta Neuropathol 99:563-70. 2000
    ....
  19. ncbi Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 115:2964-70. 2009
    ..The trial was designed to determine the maximum tolerated dose (MTD) and toxicity of irinotecan (CPT-11) when administered with temozolomide (TMZ) and O(6)-benzylguanine (O(6)-BG)...
  20. ncbi Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study
    Gamal Akabani
    Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA
    J Nucl Med 46:1042-51. 2005
    ..Further clinical studies are warranted to determine the effectiveness of (131)I-mu81C6 mAb based on a target dose of 44 Gy rather than a fixed administered activity...
  21. ncbi Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy
    Jennifer A Quinn
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 95:393-400. 2009
    ..The lack of correlation of activity with MGMT expression is intriguing, but needs further evaluation in subsequent trials...
  22. ncbi Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab
    Abraham Boskovitz
    Department of Pathology, Duke University Medical Center, Durham, NC 27710 USA
    Nucl Med Biol 36:659-69. 2009
    ..The goal of this study was to evaluate the therapeutic effect of alpha-particle emitting (211)At-labeled trastuzumab following intrathecal administration in a rat model of breast carcinoma CM...
  23. ncbi Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan
    Sith Sathornsumetee
    Department of Medicine, Duke University Medical Center, DUMC 2900, Durham, NC 27710, USA
    J Clin Oncol 26:271-8. 2008
    ....
  24. ncbi Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma
    Jennifer A Quinn
    Departments of Surgery, Duke University Medical Center, PO Box 3624, Durham, NC 27710, USA
    J Clin Oncol 27:1262-7. 2009
    ....
  25. ncbi Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience
    Christopher D Turner
    The Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 4:102-8. 2002
    ..Ongoing studies will demonstrate if activity of CPT-11 can be enhanced when combined with alkylating agents, including carmustine and temozolomide...
  26. ncbi Ham56-immunoreactive macrophages in untreated infiltrating gliomas
    T J Cummings
    Department of Pathology, Box 3712, Duke University Medical Center, Durham, NC 27710, USA
    Arch Pathol Lab Med 125:637-41. 2001
    ..The knowledge of macrophage distribution should prove useful when confronted with an infiltrating glioma containing macrophages...
  27. ncbi Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma
    Tracy Ann Read
    Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Cell 15:135-47. 2009
    ..CD15 is also found in a subset of human medulloblastomas, and tumors expressing genes similar to those found in murine CD15(+) cells have a poorer prognosis. Thus, CD15 may represent an important marker for TPCs in medulloblastoma...
  28. ncbi Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer
    Peter M Grossi
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 9:5514-20. 2003
    ..001). CONCLUSION: ICM of trastuzumab is safe and superior to systemic delivery as therapy for HER2-overexpressing intracerebral neoplasms in an athymic rat model...
  29. ncbi Brain cancer stem cells display preferential sensitivity to Akt inhibition
    Christine E Eyler
    School of Medicine, Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham North Carolina, USA
    Stem Cells 26:3027-36. 2008
    ..Together, these results suggest that Akt inhibitors may function as effective anticancer stem cell therapies...
  30. ncbi Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma
    Jill A Maxwell
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 14:4859-68. 2008
    ..The purpose of this study was to determine the role of MMR deficiency in mediating resistance in samples from patients with both newly diagnosed malignant gliomas and those who have failed temozolomide therapy...
  31. ncbi Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation
    Ryan T Mott
    Department of Pathology, Wake Forest University School of Medicine, Winston Salem, NC, USA
    J Neurosurg 108:330-5. 2008
    ..Given the important roles for EGFR and PTEN in the malignant progression of astrocytomas, the authors hypothesized that the fraction of tumor cells with aberrations in these genetic loci would correlate with the histological grade...
  32. ncbi Targeting cancer stem cells through L1CAM suppresses glioma growth
    Shideng Bao
    Department of Surgery, Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 68:6043-8. 2008
    ....
  33. ncbi OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas
    David C Adamson
    Department of Surgery, The Pediatric Brain Tumor Foundation Institute, and The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Veterans Affairs Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 70:181-91. 2010
    ..Mechanistic investigations revealed upregulation of MYC as a potential mechanism whereby OTX2 promotes tumor progression. Our findings define OTX2 as an important oncogenic driver in medulloblastoma...
  34. ncbi Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells
    Zhizhong Li
    Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Cell 15:501-13. 2009
    ..Our results demonstrate that GSCs differentially respond to hypoxia with distinct HIF induction patterns, and HIF2alpha might represent a promising target for antiglioblastoma therapies...
  35. ncbi A genetically tractable model of human glioma formation
    J N Rich
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 61:3556-60. 2001
    ..This model system will, for the first time, allow the biological significance of selected genetic alterations to be studied in human gliomas...
  36. ncbi Parasitic lesion of the insula suggesting cerebral sparganosis: case report
    T J Cummings
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Neuroradiology 42:206-8. 2000
    ..We describe the MRI appearances and pathologic features. Intracranial mass lesions secondary to sparganosis must be considered in patients with a history of travel to endemic areas, especially Asia...
  37. ncbi Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC, 27710, USA
    J Neurooncol 101:57-66. 2011
    ..In conclusion, sorafenib can be safely administered with daily temozolomide, but this regimen has limited activity for recurrent GBM. Co-administration of EIAEDs can lower sorafenib exposures in this population...
  38. ncbi Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas
    Chien Tsun Kuan
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Cancer 127:598-611. 2010
    ..These Fv-based recombinant antibodies, which possess superior tumor penetration capabilities and selectively target tumor cells that express MRP3, may potentially be used in immunotherapy and diagnosis for brain tumors and other cancers...
  39. ncbi Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6
    Michael R Zalutsky
    Department of Radiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Nucl Med 49:30-8. 2008
    ..The main goal of this study was to investigate the feasibility and safety of this approach in patients with recurrent malignant brain tumors...
  40. ncbi Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma
    Chien Tsun Kuan
    Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA
    Hybridoma (Larchmt) 28:389-403. 2009
    ..9 x 10(4) for the "glial" phenotype DAOY MED cell line and 0.6-8.8 x 10(5) for four neuronal phenotype MED cell lines. Our results indicate a potential immunotherapeutic application for these MAbs...
  41. ncbi Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma
    Duane A Mitchell
    Duke University Medical Center, Division of Neurosurgery, Department of Surgery, Durham, NC 27710, USA
    Neuro Oncol 10:10-8. 2008
    ....
  42. ncbi Single-stage bilateral choroid plexectomy for choroid plexus papilloma in a patient presenting with high cerebrospinal fluid output
    Shahid M Nimjee
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Neurosurg Pediatr 5:342-5. 2010
    ..It can result in high CSF output and can be successfully treated with a single-stage bilateral choroid plexectomy. Further studies are ongoing to identify genes involved in embryogenesis of the choroid plexus...
  43. ncbi Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas
    Annick Desjardins
    Department of Medicine, Division of Neurology, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    J Neurooncol 83:53-60. 2007
    ..We performed the current phase 2 study to evaluate this regimen among patients with recurrent WHO grade III malignant glioma (MG)...
  44. ncbi AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma
    Sith Sathornsumetee
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Res 66:8722-30. 2006
    ....
  45. ncbi Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor
    Shideng Bao
    Department of Surgery, Preston Robert Tisch Brain Tumor Center, Molecular Cancer Biology Program, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Res 66:7843-8. 2006
    ..Together these data indicate that stem cell-like tumor cells can be a crucial source of key angiogenic factors in cancers and that targeting proangiogenic factors from stem cell-like tumor populations may be critical for patient therapy...
  46. ncbi A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost
    David A Reardon
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 10:182-9. 2008
    ..S. Food and Drug Administration has approved a trial randomizing newly diagnosed GBM patients to either our study regimen or standard XRT plus temozolomide...
  47. ncbi Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Box 3050, Room 220 Sands Building, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 10:320-9. 2008
    ..However, the potential efficacy of drugs delivered by this technique may be severely constrained by ineffective infusion in many patients...
  48. ncbi Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma
    Jennifer A Quinn
    Dept of Medicine, Division of Neurology, Duke University Medical Center, Durham, NC, USA
    Neuro Oncol 11:556-61. 2009
    ..This study provides the foundation for a phase II trial of O(6)-BG in combination with a 5-day dosing schedule of TMZ in TMZ-resistant MG...
  49. ncbi Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme
    Jennifer A Quinn
    Department of Surgery, Pathology, Biostatistics, and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 15:1064-8. 2009
    ....
  50. ncbi IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain
    Giselle Y Lopez
    The Preston Robert Tisch Brain Tumor Center, The Pediatric Brain Tumor Foundation, and the Department of Pathology, Duke University Medical Center, DUMC 3156, Durham, NC 27710, USA
    Biochem Biophys Res Commun 398:585-7. 2010
    ..Studies on the cell-lineages of tumors with IDH1/2 mutations may help clarify the role of these mutations in the development of brain tumors...
  51. ncbi c-Myc is required for maintenance of glioma cancer stem cells
    Jialiang Wang
    Department of Surgery, Duke University, Durham, North Carolina, USA
    PLoS ONE 3:e3769. 2008
    ..As the c-Myc oncoprotein has recognized roles in normal stem cell biology, we hypothesized that c-Myc may contribute to cancer stem cell biology as these cells share characteristics with normal stem cells...
  52. ncbi Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 96:219-30. 2010
    ..029). Erlotinib plus sirolimus was well tolerated but had negligible activity among unselected recurrent GBM patients. (ClinicalTrials.gov number: NCT0062243)...
  53. ncbi Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 20:2277-83. 2002
    ....
  54. ncbi Splenda alters gut microflora and increases intestinal p-glycoprotein and cytochrome p-450 in male rats
    Mohamed B Abou-Donia
    Department of Pharmacology, Duke University Medical Center, Durham, North Carolina 27708, USA
    J Toxicol Environ Health A 71:1415-29. 2008
    ....
  55. ncbi Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma
    Sridharan Gururangan
    Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 10:745-51. 2008
    ..The favorable impact of HDC on disease control in the two long-term survivors cannot be clearly established due to the cofounding effect of definitive RT postrecurrence...
  56. ncbi MRP3: a molecular target for human glioblastoma multiforme immunotherapy
    Chien Tsun Kuan
    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    BMC Cancer 10:468. 2010
    ..We have identified and validated a promising molecular therapeutic target that is expressed by GBM: human multidrug-resistance protein 3 (MRP3)...
  57. ncbi EGFRvIII-targeted vaccination therapy of malignant glioma
    Bryan D Choi
    Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Brain Pathol 19:713-23. 2009
    ..Additionally, the corresponding therapeutic outcomes observed in these studies lend credence to the potential role of peptide-based vaccination strategies among emerging antitumor immunotherapies in patients with malignant glioma...
  58. ncbi Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results
    David A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA
    J Nucl Med 47:912-8. 2006
    ....
  59. ncbi Errors in surgical neuropathology and the influence of cognitive biases: the psychology of intelligence analysis
    Roger E McLendon
    Division of Neuropathology, Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Arch Pathol Lab Med 130:613-6. 2006
    ..A significant difficulty that pathologists encounter in arriving at a correct diagnosis is related to the way information from various sources is processed and assimilated in context...
  60. ncbi Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma
    David A Reardon
    AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
    Clin Cancer Res 12:860-8. 2006
    ....
  61. ncbi Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 20:1389-97. 2002
    ..To assess the efficacy and toxicity of intraresection cavity (131)I-labeled murine antitenascin monoclonal antibody 81C6 and determine its true response rate among patients with newly diagnosed malignant glioma...
  62. ncbi Phase II trial of temozolomide in patients with progressive low-grade glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 21:646-51. 2003
    ..We have extended these results, and now we report results of a phase II trial of Temodar for patients with progressive, low-grade glioma...
  63. ncbi Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study
    John H Sampson
    Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 7:90-6. 2005
    ..This report describes a dramatic and sustained clinical and radiographic response in a patient with a bifrontal glioblastoma multiforme treated with intratumoral infusion of a novel targeted toxin, TP-38...
  64. ncbi Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
    Ranjit K Goudar
    Department of Pathology, Duke University Medical Center, P O Box 2900, Durham, NC 27710, USA
    Mol Cancer Ther 4:101-12. 2005
    ..These studies suggest that simultaneous inhibition of growth factor receptor and mTOR pathways offer increased benefit in glioma therapy...
  65. ncbi Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas
    Daniel K Broderick
    Brain Tumor Center, Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Res 64:5048-50. 2004
    ..These observations implicate PIK3CA as an oncogene in a wider spectrum of adult and pediatric brain tumors and suggest that PIK3CA may be a useful diagnostic marker or a therapeutic target in these cancers...
  66. ncbi Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects
    Roger E McLendon
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Nucl Med Biol 34:405-13. 2007
    ....
  67. ncbi Molecular markers of prognosis in astrocytic tumors
    Ahmed Rasheed
    Department of Pathology, Duke University Medical Center, 3156, Durham, NC 27710, USA
    Cancer 94:2688-97. 2002
    ..To date, only age and histologic grade stand out as independent predictors of survival. There is now increased interest in the use of molecular markers as objective standards against which to establish diagnosis and grade...
  68. ncbi Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant b
    John H Sampson
    Division of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 65:27-35. 2003
    ..9 weeks. Overall, 3 of 15 patients, with residual disease at the time of therapy, have demonstrated radiographic responses and one patient with a complete response and has survived greater than 83 weeks...
  69. ncbi Phase II trial of gefitinib in recurrent glioblastoma
    Jeremy N Rich
    Duke University Medical Center, Box 2900, Durham, NC 27710, USA
    J Clin Oncol 22:133-42. 2004
    ..To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma...
  70. ncbi Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis
    Gamal Akabani
    Department of Radiology, Duke University Medical Center, Box 3808, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 54:1259-75. 2002
    ..To establish the theoretical framework and study the feasibility of (211)At-labeled anti-tenascin chimeric 81C6 monoclonal antibody (mAb) as anti-vascular endoradiotherapy for the treatment of glioblastoma multiforme (GBM) tumors...
  71. ncbi High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas
    Sridharan Gururangan
    Brain Tumor Center at Duke and the Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 21:2187-91. 2003
    ..We evaluated the usefulness of a treatment regimen that included high-dose chemotherapy (HDC) with autologous stem-cell rescue (ASCR) in patients with newly diagnosed pineoblastoma (PBL)...
  72. ncbi Gene expression profiling and genetic markers in glioblastoma survival
    Jeremy N Rich
    Department of Medicine, W M Keck Center for Neuro Oncogenomics, Institute of Statistics and Decision Sciences, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 65:4051-8. 2005
    ....
  73. ncbi Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC, USA
    J Clin Oncol 23:7178-87. 2005
    ..In addition, plasma concentrations of O6-BG and O6-benzyl-8-oxoguanine were evaluated after O6-BG...
  74. ncbi ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors
    Jeremy N Rich
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 11:8145-57. 2005
    ..Current nonspecific therapies frequently have poor efficacy in many of these tumor types, so there is a pressing need for the development of novel targeted therapies...
  75. ncbi Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results
    David A Reardon
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC, 27710, USA
    J Clin Oncol 24:115-22. 2006
    ..To assess the efficacy and toxicity of intraresection cavity iodine-131-labeled murine antitenascin monoclonal antibody 81C6 (131I-m81C6) among recurrent malignant brain tumor patients...
  76. ncbi Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme
    David A Reardon
    Department of Medicine, Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA
    J Clin Oncol 23:9359-68. 2005
    ....
  77. ncbi Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas
    S Gururangan
    Department of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 3:246-50. 2001
    ..Our study demonstrates that TEMO can be given safely after placement of Gliadel (3.85%) wafers. The recommended dosage for TEMO for a phase II study of this combination is 200 mg/m2 per day for 5 days...
  78. ncbi Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25
    B K Rasheed
    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Oncogene 10:2243-6. 1995
    ..In the 15 tumors with deletions in 10q, the minimal overlapping deletion region was in distal 10q between markers D10S587 and D10S216. Loci D10S587 and D10S216 are approximately mapped to a 5 cM region in 10q25.1...
  79. ncbi CD34 and dural fibroblasts: the relationship to solitary fibrous tumor and meningioma
    T J Cummings
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Acta Neuropathol 102:349-54. 2001
    ..Our results suggest that SFTs and dural-based fibrous nodules derive from CD34-positive dural-based fibroblasts, and that CD34 reactivity in meningiomas may result from inclusion of dural fibroblasts within the neoplasm...
  80. ncbi A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation
    Yukinari Kato
    Department of Pathology, Duke University Medical Center, DUMC 3156, Durham, NC 27710, USA
    Biochem Biophys Res Commun 390:547-51. 2009
    ..In conclusion, we established an anti-IDH1(R132H)-specific monoclonal antibody IMab-1, which should be significantly useful for diagnosis and biological evaluation of mutation-bearing gliomas...
  81. ncbi Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma
    A B Heimberger
    Division of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
    J Neuroimmunol 103:16-25. 2000
    ..Therefore, in a murine model, vaccination with DCs pulsed with glioma tumor homogenate is a safe and effective therapy against a syngeneic glioma located in the immunologically privileged central nervous system (CNS)...
  82. ncbi Castleman's disease confined to the leptomeninges
    T J Cummings
    Duke University Medical Center, Durham, North Carolina, Department of Pathology, 27710, USA
    Ann Clin Lab Sci 30:278-82. 2000
    ..The patient is disease-free five years after surgical resection. To our knowledge, clonal gene rearrangement has not been previously reported in the plasma cell variant of localized intracranial Castleman's disease...
  83. ncbi Meningioma with eosinophilic granular inclusions
    R T Alexander
    Duke University Medical Center, Durham, NC, USA
    Clin Neuropathol 23:292-7. 2004
    ..The inclusions within this tumor had histochemical, immunohistochemical and ultrastructural properties not described in other reported meningiomas with eosinophilic granular or granulofilamentous inclusions...
  84. ncbi Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas
    C J Wikstrand
    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 55:3140-8. 1995
    ..Our observations strongly warrant development of this mAb-antigen system as therapy for breast, lung, and central nervous system tumors...
  85. ncbi March 2000: A 16 year old female with a cerebellar mass
    T J Cummings
    Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA
    Brain Pathol 11:391-3. 2001
    ..Patient's diagnosed with Lhermitte-Duclos disease must be adequately evaluated for Cowden's syndrome...
  86. ncbi Endodermal cyst of the oculomotor nerve
    M A Morgan
    School of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Neuroradiology 43:1063-6. 2001
    ..She underwent craniotomy, biopsy, slit resection, and drainage of the cyst. To our knowledge, endodermal cysts have not been previously described in relation to the oculomotor nerve...
  87. ncbi The pathology of extracranial scalp and skull masses in young children
    T J Cummings
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Clin Neuropathol 23:34-43. 2004
    ..Although the most common reported lesion is the dermoid cyst, our experience suggests that the spectrum of pathology in these lesions can present diagnostic challenges to the pathologist...
  88. ncbi Fine-needle aspiration cytology of "ancient" schwannoma
    L G Dodd
    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Diagn Cytopathol 20:307-11. 1999
    ..The FNA features of ancient schwannoma are important to note because of the potential to confuse this lesion with a more serious one such as sarcoma on FNA...
  89. ncbi Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium
    Nancy D Doolittle
    Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road-L603, Portland, OR 97201-3098, USA
    Clin Cancer Res 8:1702-9. 2002
    ....
  90. ncbi MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group
    Naji Aldosari
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Arch Pathol Lab Med 126:540-4. 2002
    ..Intratumoral heterogeneity was identified for these oncogenes in that 1 patient's tumor exhibited evidence of both MYCN and MYCC amplification, and this patient experienced a shortened survival time...
  91. ncbi Recurrent glioblastoma diagnosed by fluorescence in situ hybridization for EGFR
    M Natalie Grunkemeier
    Acta Neuropathol 113:217-9. 2007
  92. ncbi MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy
    Kalman Kovacs
    Acta Neuropathol 115:261-2. 2008
  93. ncbi Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications
    Rodney N Wiltshire
    Duke University Medical Center, Department of Pathology, Box 3712, Durham, NC 27710, USA
    J Mol Diagn 6:166-79. 2004
    ..The cumulative effect of these loci is an important consideration in their diagnostic and prognostic implications...
  94. ncbi A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group
    Murali M Chintagumpala
    Baylor College of Medicine, 6621 Fannin, CC 1510 00, Houston, TX, USA
    J Neurooncol 77:193-8. 2006
    ..Future trials should consider strategies to overcome the resistance mechanisms in children with high-grade glioma...
  95. ncbi Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid
    Chunhui Di
    Brain Tumor Center, Department of Pathology, Duke University Medical Center, Research Drive, Durham, NC 27710, USA
    Cancer Res 65:919-24. 2005
    ..These observations suggest that OTX2 is essential for the pathogenesis of anaplastic medulloblastomas and that these tumors may be amenable to therapy with all-trans-retinoic acid...
  96. ncbi Protocol for the examination of specimens from patients with tumors of the brain/spinal cord
    Joseph E Parisi
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Arch Pathol Lab Med 132:907-12. 2008
  97. ncbi Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
    Shideng Bao
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Nature 444:756-60. 2006
    ..Targeting DNA damage checkpoint response in cancer stem cells may overcome this radioresistance and provide a therapeutic model for malignant brain cancers...
  98. ncbi Correlation of 1p-19q-defects in human gliomas with the light microscopic appearance of oligodendroglioma
    Roger E McLendon
    Mod Pathol 17:604-5. 2004
  99. ncbi Is the long-term survival of patients with intracranial glioblastoma multiforme overstated?
    Roger E McLendon
    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 98:1745-8. 2003
    ..Conventionally treated patients with GBM, chosen from an unselected population from a tumor registry, have a smaller chance of long-term survival than is generally believed...
  100. ncbi Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma
    Lars M Wagner
    Division of Pediatric Hematology Oncology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
    Clin Cancer Res 13:5418-25. 2007
    ..We hypothesized that the DNA repair protein methylguanine-DNA methyltransferase (MGMT) is an important resistance factor, and that inactivation of MGMT would sensitize neuroblastoma cells to these agents...
  101. ncbi Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin
    Hidenobu Ochiai
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Neurol Med Chir (Tokyo) 46:485-9; discussion 489-90. 2006
    ..005). These results suggest that intrathecal treatment with 9NC may be useful for patients with GBM neoplastic meningitis...